Wearable Device Monitoring After Hospital Stay for Heart Failure

Trial details

Who runs it

Zoll Medical Corporation

Trial code

NCT07622472

Record updated

5 October 2026

Original description

Heart failure is a condition in which the heart cannot pump blood effectively, often leading to symptoms such as shortness of breath and fluid retention. After hospitalization for heart failure, patients remain at high risk of worsening symptoms, emergency visits, and hospital readmission.Read full original descriptionShow less

Remote Monitoring and Optimization of Heart Failure Therapy

Heart failure is a condition in which the heart cannot pump blood effectively, often leading to symptoms such as shortness of breath and fluid retention. After hospitalization for heart failure, patients remain at high risk of worsening symptoms, emergency visits, and hospital readmission.

This study is designed to evaluate whether using a wearable monitoring device, called the Heart Failure Management System (HFMS), can help improve the management of patients after a recent hospitalization for heart failure.

Participants in this study will be randomly assigned to one of two groups. One group will receive standard medical care alone. The other group will receive standard medical care in combination with the HFMS device. The HFMS device is worn on the body and continuously collects information such as heart rate, breathing, activity level, and signs of fluid accumulation. These data are reviewed by the clinical care team and may help detect early worsening of heart failure.

Participants will wear the device for 90 days (if assigned to the device group) and will be followed for up to one year. During the study, information will be collected on serious health events such as death, hospitalizations, emergency visits, and changes in heart failure status, as well as quality of life.

The goal of this study is to determine whether this monitoring approach can improve outcomes for patients with heart failure by enabling earlier and more effective clinical management.

Inclusion: Age ≥18 years; Ability and willingness to provide written informed consent and comply with study procedures; Hospital admission for acute heart failure with dyspnea at rest and pulmonary congestion on chest X-ray, and other signs and/or symptoms of heart failure such as edema and/or positive rales on auscultation; All measures within 24 hours prior to randomization of systolic blood pressure ≥ 100 mmHg, and of heart rate ≥ 60 bpm; All measures within 24 hours prior to randomization of serum potassium ≤ 5.5 mEq/L (mmol/L); Biomarker criteria for persistent congestion:; NT-proBNP >1500 pg/mL at the time of admission, and; NT-proBNP >1000 pg/mL >=3 days after initial admission measure; At 1 week prior to admission, either (a) ≤ ½ the optimal dose of ACEi/ARB/ARNi (see Table) prescribed, no beta-blocker prescribed, and ≤ ½ the optimal dose of MRA prescribed or (b) no ACEi/ARB/ARNi prescribed, ≤ ½ the optimal dose of beta-blocker prescribed, and ≤ ½ the optimal dose of MRA prescribed. All study participants prescribed per label and commercially fit with the HFMS device will be eligible for enrollment.

Exclusion: Mechanical ventilation (not including CPAP/BIPAP) in the 24 hours prior to Screening; Cardiac surgery within 3 months prior to Screening; Index Event (admission for AHF) triggered primarily by a correctable etiology such as significant arrhythmia (e.g., sustained ventricular tachycardia, or atrial fibrillation/flutter with sustained ventricular response >130 beats per minute, or bradycardia with sustained ventricular arrhythmia <45 beats per minute), severe anemia, acute coronary syndrome, pulmonary embolism, planned admission for device implantation or severe nonadherence leading to very significant fluid accumulation prior to admission and brisk diuresis after admission. Troponin elevations without other evidence of an acute coronary syndrome are not excluded; Pulmonary artery pressure implant (e.g. CardioMems); Significant pulmonary disease contributing substantially to the patients' dyspnea such as FEV1< 1 liter or need for chronic systemic or nonsystemic steroid therapy, or any kind of primary right heart failure such as precapillary pulmonary hypertension or chronic thromboembolic pulmonary hypertension; Uncorrected thyroid disease, active myocarditis, or known amyloid, sarcoidosis, or hypertrophic obstructive cardiomyopathy; History of heart transplant or on a transplant list, or using or planned to be implanted with a ventricular assist device; Adhesive allergy/sensitivity (e.g., acrylic adhesives); Age < 18 years; Clearly documented intolerance to high doses (≥50% of target dose) of beta-blockers; Clearly documented intolerance to high doses (≥50% of target dose) of RAS blockers (both ACEi and ARB); Compromised skin at the device application site (wound, severe dermatitis, etc.) ; Having a prescribed wearable cardioverter defibrillator; Expected survival <1 year.

ClinicalTrials.gov NCT07622472